Novel dual Src/Abl inhibitors for hematologic and solid malignancies

Bibliography

• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42
   PubMed Web of Science ®Google Scholar
• Schenone S, Manetti F, Botta M. Synthetic SRC-kinase domain inhibitors and their structural requirements. Anticancer Agents Med Chem 2007;7:660-80
   PubMed Web of Science ®Google Scholar
• Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-86
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30
   PubMed Web of Science ®Google Scholar
• Fernandes MS, Reddy MM, Gonneville JR, BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009;114:1813-9
   PubMed Web of Science ®Google Scholar
• Schenone S, Bruno O, Radi M, Botta M. New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 2009. [Epub ahead of print]
   Google Scholar
• Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of Abl and Src tyrosine-kinases. Mini Rev Med Chem 2007;7:191-201
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CY, The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7
   PubMed Web of Science ®Google Scholar
• Konig H, Copland M, Chu S, Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008;68:9624-33
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009;4:3-10
   PubMed Web of Science ®Google Scholar
• Snyder DS. New approved dasatinib regimen available for clinical use. Expert Rev Anticancer Ther 2009;9:285-92
   PubMed Web of Science ®Google Scholar
• Bryant G. A once-daily dasatinib dosing strategy for chronic myeloid leukemia. Clin J Oncol Nurs 2009;19:316-23
   Web of Science ®Google Scholar
• Khoury HJ, Guilhot F, Hughes TP, Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009;115:1381-94
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundan T, Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-12
   PubMed Web of Science ®Google Scholar
• Chen Y, Agarwal S, Shaik NM, P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009;330:956-63
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-83
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim DW, Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-47
   PubMed Web of Science ®Google Scholar
• Muller MC, Cortes JE, Kim DW, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-53
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Botta M. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr Med Chem 2010;17:1220-45
   PubMed Web of Science ®Google Scholar
• Soverini S, Gnani A, Colarossi S, Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168-71
   PubMed Web of Science ®Google Scholar
• Yang C, Lu P, Lee FY, Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22:1755-66
   PubMed Web of Science ®Google Scholar
• Hollmann CA, Tzankov A, Martinez-Marignac VL, Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leuk Res 2010;34:585-93
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Ginther C, Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ “triple-negative” breast cancer cell lines growing in vitro. Breast Cacer Res Treat 2007;105:319-26
   PubMed Web of Science ®Google Scholar
• Pichot CS, Hartig SM, Xia L, Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009;101:38-47
   PubMedGoogle Scholar
• Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434-40
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33
   PubMed Web of Science ®Google Scholar
• Koreckij T, Nguyen H, Brown LG, Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263-8
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8
   PubMed Web of Science ®Google Scholar
• Kopetz S. Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res 2007;1:S37-41
   PubMedGoogle Scholar
• Kopetz S, Lesslie DP, Dallas NA, Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69:3842-9
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81
   PubMed Web of Science ®Google Scholar
• Trevino JG, Summy JM, Lesslie DP, Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-72
   PubMed Web of Science ®Google Scholar
• Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 2008;99:1074-82
   PubMed Web of Science ®Google Scholar
• Lau GM, Lau GM, Yu GL, Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 2009;54:1465-74
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32
   PubMed Web of Science ®Google Scholar
• Yoshida T, Okamoto I, Okamoto W, Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010;101:167-72
   PubMed Web of Science ®Google Scholar
• Ceppi P, Papotti M, Monica V, Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009;8:3066-74
   PubMed Web of Science ®Google Scholar
• Byers LA, Sen B, Saigal B, Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61
   Google Scholar
• Haura EB, Tanvetyanon T, Chiappori A, J Clin Oncol Phase I/II Study of the Src inhibitor Dasatinib in combination with Erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1387-94
   PubMed Web of Science ®Google Scholar
• Miller AA, Pang H, Hodgson L, A Phase II study of Dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 2010;5:380-4
   PubMed Web of Science ®Google Scholar
• de Groot J, Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol 2009;95:151-63
   PubMed Web of Science ®Google Scholar
• Milano V, Piao Y, LaFortune T, de Groot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 2009;8:394-406
   PubMed Web of Science ®Google Scholar
• Du J, Bernasconi P, Clauser KR, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009;27:77-83
   PubMed Web of Science ®Google Scholar
• Homsi J, Cubitt CL, Zhang S, Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009;19:167-75
   PubMed Web of Science ®Google Scholar
• Buettner R, Mesa T, Vultur A, Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008;6:1766-74
   PubMed Web of Science ®Google Scholar
• Eustace AJ, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 2008;6:53
   PubMed Web of Science ®Google Scholar
• Woodman SE, Trent JC, Stemke-Hale K, Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009;8:2079-85
   PubMed Web of Science ®Google Scholar
• Vitali R, Mancini C, Cesi V, Tanno B. Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int J Cancer 2009;125:2547-55
   PubMed Web of Science ®Google Scholar
• Demetri GD, Lo Russo P, MacPherson IR, Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40
   PubMed Web of Science ®Google Scholar
• Johnson FM, Agrawal S, Burris H, Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Ye F, Wang YD, Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001;44:3965-77
   PubMed Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C, SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-85
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-22
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian HM, Kim DW, Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood (Ash Annu Meeting Abstr) 2008;112: abstract 1098
   Web of Science ®Google Scholar
• Golas JM, Lucas J, Etienne C, SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65(12):5358-64
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Boschelli F. Bosutinib. Dual Src and Abl kinase inhibitor, treatment of solid tumors, treatment of CML and Ph+ ALL. Drugs Future 2007;32:481-90
   Web of Science ®Google Scholar
• Jallal H, Valentino ML, Chen G, A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007;67:1580-8
   PubMed Web of Science ®Google Scholar
• Vultur A, Buettner R, Kowolik C, SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008;7:1185-94
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Rajeshkumar NV, Tan AC, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009;8:1484-93
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Allen J, Breed J, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006;49:6465-88
   PubMed Web of Science ®Google Scholar
• Mambou Gwanmesia P, Romanski A, Schwarz K, The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 2009;9:53
   PubMed Web of Science ®Google Scholar
• Green TP, Fennell M, Whittaker R, Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3:248-61
   PubMed Web of Science ®Google Scholar
• Hiscox S, Jordan NJ, Smith C, Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115:57-67
   PubMed Web of Science ®Google Scholar
• Chen Y, Guggisberg N, Jorda M, Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009;15:3396-405
   PubMed Web of Science ®Google Scholar
• Chang YM, Bai L, Liu S, Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75
   PubMed Web of Science ®Google Scholar
• Yang JC, Ok JH, Busby JE, Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Longmate J, Evans CP, A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009;20:179-84
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, Tan AC, De Oliveira E, Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009;15:4138-46
   PubMed Web of Science ®Google Scholar
• Pham NA, Magalhaes JM, Do T, Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 2009;124:280-6
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M, Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose Phase I trial. J Bone Miner Res 2010;25:463-71
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cervantes A, Hoekman K, Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of Src inhibition of Src activity in human cancers. J Clin Oncol ASCO Meeting Abstracts 2007;25:3520
   Web of Science ®Google Scholar
• Azam M, Nardi V, Shakespeare WC, Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103:9244-9
   PubMed Web of Science ®Google Scholar
• Huang WS, Zhu X, Wang Y, 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem 2009;52:4743-56
   PubMed Web of Science ®Google Scholar
• Azam M, Powers JT, Einhorn W, AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des 2010;75:223-7
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Kasap C, Paquette R, Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood (ASH Annual Meeting Abstracts) 2007;110:474
   Google Scholar
• Noronha G, Barrett K, Boccia A, Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine - a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett 2007;17:602-8
   PubMed Web of Science ®Google Scholar
• Hu SX, Soll R, Yee S, Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). Drug Metab Dispos 2007;35:929-36
   PubMed Web of Science ®Google Scholar
• Van Etten RA, Chan WW, Zaleskas VM, DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood (ASH Annual Meeting Abstracts) 2007;110:463
   Google Scholar
• Carraro F, Pucci A, Naldini A, Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem 2004;47:1595-8
   PubMed Web of Science ®Google Scholar
• Carraro F, Naldini A, Pucci A, Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 2006;49:1549-61
   PubMed Web of Science ®Google Scholar
• Manetti F, Santucci A, Locatelli GA, Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 2007;50:5579-88
   PubMed Web of Science ®Google Scholar
• Santucci MA, Corradi V, Mancini M, C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. ChemMedChem 2009;4:118-26
   PubMed Web of Science ®Google Scholar
• Spreafico A, Schenone S, Serchi T, Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008;22:1560-71
   PubMed Web of Science ®Google Scholar
• Celano M, Schenone S, Cosco D, Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer 2008;15:499-510
   PubMed Web of Science ®Google Scholar
• Rossi A, Schenone S, Angelucci A, New pyrazolo-[3,4-d]-pyrimidine derivatives Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J 2010; In press
   Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond – exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535-43
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008;34:37-48
   PubMed Web of Science ®Google Scholar
• Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7
   PubMed Web of Science ®Google Scholar
• Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009;5:616-24
   PubMed Web of Science ®Google Scholar
• Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004;3:179-96
   PubMed Web of Science ®Google Scholar
• Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 2004;22:1253-9
   PubMed Web of Science ®Google Scholar
• Tatonetti NP, Liu T, Altman RB. Predicting drug side-effects by chemical systems biology. Genome Biol 2009;10:238
   PubMed Web of Science ®Google Scholar
• Sylvester JE, Kron SJ. A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. Mol Cancer Ther 2010;9:1469-81
   PubMed Web of Science ®Google Scholar
• Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009;25:2466-72
   PubMed Web of Science ®Google Scholar